Protein delivery opportunity
Many potentially useful therapeutic proteins cannot efficiently cross retinal cell membranes. Nuc1 is designed to address that bottleneck directly.
Core technology
Designed to move therapeutic payloads into hard‑to‑reach ocular tissues.
Visiogene’s platform strategy combines engineered AAV delivery with a cell‑penetrating chaperone that expands the range of molecules that can be delivered to retinal cells.
AAV‑IKVNuc1IntravitrealIntracameralOuter retinaAnterior segment
AAV‑IKV
A retinal penetrating AAV vector.
AAV‑IKV incorporates a short IKV sequence into an AAV9 capsid context, creating a vector designed for transgene delivery to outer retinal targets from an intravitreal route in preclinical studies.
Platform capabilities
Gene delivery to ocular targets
- Preclinical transgene expression in photoreceptors and retinal pigment epithelium after intravitreal administration
- Potential to replace surgically created subretinal access for selected retinal targets
- Anterior chamber delivery to cornea, ciliary body, and trabecular meshwork in glaucoma studies
- Payload flexibility for anti‑fibrotic, anti‑angiogenic, antioxidant, and complement-modulating strategies
Nuc1
Cell‑penetrating chaperone for biologics.
Nuc1 is designed to engage retinal cell uptake and assist intracellular delivery of diverse cargo without requiring chemical conjugation.
No conjugationCo‑administration design
Broad cargoProteins, antibodies, peptides, AAV
Retinal uptakeInner and outer retinal cells
Combination usePlatform enhancer
AAV delivery enhancement
Nuc1 has been used with AAV‑IKV to enhance ocular transduction in preclinical studies, providing a modular delivery layer.
Payload optionality
The platform creates room for recombinant protein therapies, gene editing protein cargo, antibody delivery, and vector delivery strategies.
How the platforms fit together
A modular delivery engine.
AAV‑IKV is the durable transgene expression platform. Nuc1 is the delivery chaperone. Together, they support both owned product candidates and partnering applications.
Outer retinal delivery
Programs can target photoreceptors, RPE, and choroidal neovascularization biology through intravitreal delivery.
Trabecular meshwork access
AAV‑IKV supports intracameral delivery hypotheses for glaucoma and infantile aphakic glaucoma biology.
Protein and large cargo
Nuc1 may enable intracellular protein delivery strategies that are not practical with conventional intraocular biologics.
Science
Review the data package behind AAV‑IKV and Nuc1.
Visiogene’s platform science supports a focused pipeline across retinal and anterior segment disease.